**The Mitochondrial Permeability Transition Pore and its Role in**

**Myocardial Ischemia Reperfusion Injury**

Sang-Bing Ong, Parisa Samangouei, Siavash Beikoghli Kalkhoran,

Derek J Hausenloy

The Hatter Cardiovascular Institute,

Institute of Cardiovascular Science,

NIHR University College London Hospitals Biomedical Research Centre,

University College London Hospital & Medical School,

67 Chenies Mews, London, WC1E 6HX, UK.

**Corresponding author:**

Prof Derek J Hausenloy

The Hatter Cardiovascular Institute,

Institute of Cardiovascular Science,

NIHR University College London Hospitals Biomedical Research Centre,

University College London Hospital & Medical School,

67 Chenies Mews, London, WC1E 6HX, UK.

Tel:  +44 (203) 447 9894

Fax: +44 (203) 447 9505

E-mail: d.hausenloy@ucl.ac.uk

**Abstract**

Ischemic heart disease (IHD) remains the leading cause of death and disability worldwide. For patients presenting with an acute myocardial infarction, the most effective treatment for limiting myocardial infarct (MI) size is timely reperfusion. However, in addition to the injury incurred during acute myocardial ischemia, the process of reperfusion can itself induce myocardial injury and cardiomyocyte death, termed ‘myocardial reperfusion injury’, the combination of which can be referred to as acute ischemia-reperfusion injury (IRI). Crucially, there is currently no effective therapy for preventing this form of injury, and novel cardioprotective therapies are therefore required to protect the heart against acute IRI in order to limit MI size and preserve cardiac function. The opening of the mitochondrial permeability transition pore (MPTP) in the first few minutes of reperfusion is known to be a critical determinant of IRI, contributing up to 50% of the final MI size. Importantly, preventing its opening at this time using MPTP inhibitors, such as cyclosporin-A, has been reported in experimental and clinical studies to reduce MI size and preserve cardiac function. However, more specific and novel MPTP inhibitors are required to translate MPTP inhibition as a cardioprotective strategy into clinical practice. In this article, we review the role of the MPTP as a mediator of acute myocardial IRI and as a therapeutic target for cardioprotection.

**Highlights**

* Myocardial ischaemia-reperfusion injury (IRI) is a neglected therapeutic target.
* Mitochondrial permeability transition pore (MPTP) opening mediates myocardial IRI.
* Inhibiting MPTP opening at reperfusion protects the heart against myocardial IRI.
* Ischemic conditioning protects the heart by inhibiting MPTP opening at reperfusion.
* MPTP inhibition can reduce myocardial IRI in patients with ischaemic heart disease.

**Keywords**

Ischemic heart disease, Myocardial infarction, Myocardial ischemia-reperfusion Injury, Mitochondrial permeability transition pore, Cardioprotection.

**List of Abbreviations**

ADP Adenosine diphosphate

ANT Adenine nucleotide translocase

ATP Adenosine triphosphate

Ca2+ Calcium ion

CABG Coronary artery bypass graft

cGMP Cyclic guanosine 3’,5’-monophosphate

CK-MB Creatine kinase

Cl- Chloride ion

CsA Cyclosporin-A

CypD Cyclophilin D

Drp1 Dynamin-related protein 1

ER Endoplasmic reticulum

Erk Extracellular signal-regulated kinase

GSH Reduced glutathione

GSK Glycogen synthase kinase

GSSG Oxidized glutathione

GST Glutathione S-transferase

H+ Hydrogen ion

HCO3- Hydrogen carbonate ion

hFis1 Human Fission protein 1

HK Hexokinase

IHD Ischemic heart disease

IMM Inner mitochondrial membrane

IPC Ischemic preconditioning

IPost Ischemic postconditioning

IR Ischemia reperfusion

IRI Ischemia-reperfusion injury

LV Left ventricular

MCU Mitochondrial calcium uniporter

MI Myocardial infarct

MitoKATP Mitochondrial ATP-sensitive potassium channel

MPTP Mitochondrial permeability transition pore

MRI Magnetic resonance imaging

Na+ Sodium ion

NO Nitric oxide

NOS Nitric oxide synthase

NHE Sodium hydrogen exchanger

OMM Outer mitochondrial membrane

Opa1 Optic atrophy 1

Pi Inorganic phosphates

PiC Mitochondrial phosphate carrier

PKA Protein kinase A

PKB Protein kinase B

PKC-ε Protein kinase C-epsilon

PKG Protein kinase G

PPCI Primary percutaneous coronary intervention

PPIF peptidylprolylisomerase F

RIC Remote ischemic conditioning

RISK Reperfusion injury signaling kinase

RNA Ribonucleic acids

ROS Reactive oxygen species

SAFE Survivor Activating Factor Enhancement

siRNA Small interfering RNA

STAT-3 Signal transducer and activator of transcription 3

STEMI ST segment elevation myocardial infarction

TIMI Thrombolysis in Myocardial Infarction

VDAC Voltage-dependent anion channel

ΔΨm Mitochondrial membrane potential

*Clinical Studies:*

CYCLE CYCLosporine A in Reperfused Acute Myocardial Infarction

CIRCUS Cyclosporine and Prognosis in Acute Myocardial Infarction Patients

CLOTILDE Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock

1. **Introduction**

Ischemic heart disease (IHD) is the leading cause of death and disability in the world, with over 1.9 million and 600,000 deaths per year, in Europe (<http://www.escardio.org/about/what/advocacy/EuroHeart/Pages/2012-CVD-statistics.aspx>) and the United States (http://www.cdc.gov/heartdisease/facts.htm), respectively. Although mortality rates from IHD appear to be falling in the developed world, survival after heart failure has decreased over the last few years [1]. The major clinical manifestations of IHD result in the heart being subjected to acute ischemia-reperfusion injury (IRI), the detrimental effects of which are myocardial injury, cardiomyocyte death and cardiac dysfunction, resulting in cardiac arrhythmias, heart failure and death. Apart from limiting acute myocardial ischemic injury by timely reperfusion, there is currently no effective therapeutic intervention for protecting the heart against acute IRI, and therefore, novel cardioprotective therapies are still required to improve clinical outcomes in patients with IHD [2,3].

In this regard, the mitochondrial permeability transition pore (MPTP) has emerged as a critical mediator of acute IRI, thereby making it an important target for cardioprotection. Experimental animal studies have shown that pharmacologically inhibiting MPTP opening can reduce myocardial infarct (MI) size, a therapeutic strategy which has been reported in initial proof-of-concept clinical studies to be beneficial [4-8]. However, in order to translate this therapeutic strategy into the clinical setting, more novel, specific and potent MPTP inhibitors will need to be discovered, an objective which will be easier to achieve once the molecular identity of the MPTP has been confirmed. In this article we review the role of the MPTP as a key determinant of acute myocardial IRI, and we investigate MPTP inhibition as a cardioprotective strategy for potentially improving clinical outcomes in patients with IHD.

1. **Myocardial reperfusion injury as a neglected therapeutic target**

For patients presenting with an acute ST-segment elevation myocardial infarction (STEMI), the treatment of choice is to reperfusion using primary percutaneous coronary intervention (PPCI). Although essential to salvage viable myocardium, the process of reperfusion can in itself induce myocardial injury and cardiomyocyte death, a process which has been termed ‘myocardial reperfusion injury’. This can contribute up to 50% of the final myocardial infarct size. Importantly, although procedures are in place to limit the duration of acute myocardial ischemia in STEMI patients, such as rapid ambulance transfer to PPCI centers, there is currently no effective therapy for preventing myocardial reperfusion injury, making it a neglected therapeutic target for improving clinical outcomes in patients with IHD.

Four types of myocardial reperfusion injury have been described [2]: (1) Reperfusion arrhythmias, which occur commonly, are often self-terminating, and are relatively easy to manage; (2) Myocardial stunning, which refers to reversible acute cardiac contractile dysfunction; (3) Microvascular obstruction which describes an inability to perfuse myocardium at the microvascular level and which manifests as coronary no-reflow at time of angiography; and (4) Lethal reperfusion injury, which refers to the death of cardiomyocytes which were still viable at the end of ischemia, and contributes to the final MI size. In this review article, we will focus on this latter form of myocardial reperfusion injury as this represents an important target for cardioprotection.

For STEMI patients treated by the reperfusion strategy PPCI, the resultant MI size is often larger than expected for the duration of acute myocardial ischemia - this additional increase in MI size is due to the existence of lethal myocardial reperfusion injury. Consequently, the benefits of reperfusion are mitigated in terms of myocardial salvage and reduction in MI size. The most important experimental evidence supporting the existence of lethal myocardial reperfusion injury as an independent mediator of cardiomyocyte death is the observation that a therapeutic intervention applied solely at the onset of reperfusion can reduce MI size by as much as 50% [2]. The major event which is precipitated by the onset of reperfusion and which is the key mediator of lethal reperfusion injury is the opening of the MPTP.

1. **The MPTP as a critical mediator of myocardial reperfusion injury**

The MPTP was first characterized in seminal experimental studies from the late 1970s by Haworth and Hunter [9-12]. It refers to the mitochondrial channel which mediates the abrupt change, or transition, in inner mitochondrial membrane permeability which occurs under certain conditions. The opening of the MPTP renders the inner mitochondrial membrane (IMM) non-selectively permeable to molecules less than 1.5 kDa, collapsing the mitochondrial membrane potential, uncoupling oxidative phosphorylation, leading to ATP depletion and cell death[4,8]. Another important effect of MPTP opening is mitochondrial matrix swelling and OMM rupture resulting in the deposition of pro-apoptotic factors such as cytochrome *c* from the inter-membranous space into the cytosol, thereby initiating apoptotic cell death.

It was not until the mid to late 1980s in pioneering experimental studies by Crompton’s group that the MPTP was first investigated as a potential mediator of acute myocardial IRI [13-15]. In these early studies it was demonstrated that MPTP opening in isolated liver and cardiac mitochondria was regulated by factors such as Ca2+, inorganic phosphate, oxidative stress, and ADP [13-15]. Crucially, these factors are modulated during acute IRI and act to induce MPTP opening in this setting. By measuring mitochondrial entrapment of titriated glucose (termed the Hot-DOG technique) [16] in perfused rat hearts, Griffiths and Halestrap [17] made the crucial discovery that the MPTP remained closed during acute myocardial ischemia, and only opened in the first few minutes of reperfusion. The acidic conditions induced by lactic acid accumulation during acute myocardial ischemia (pH < 7.0) exert a strong inhibitory effect on the MPTP [18] despite the presence of inducing factors such as Ca2+ and inorganic phosphate overload, oxidative stress, and ADP. In the first few minutes of reperfusion, the rapid washout of lactic acid and the re-activation of the Na+-H+ ion exchanger and Na+-HCO3-symporter, restores physiological pH at the onset of reperfusion, thereby permitting MPTP opening at this time.

1. **The MPTP as a target of cardioprotection**

The important finding in 1988 by Crompton’s group that MPTP opening could be inhibited by the immunosuppressant, cyclosporin-A (CsA), has facilitated the investigation of the MPTP as a mediator of acute IRI and a target of cardioprotection (reviewed in [7]). Crompton and colleagues were the first to use CsA to investigate the MPTP as a target for cardioprotection [19]. They found that pre-treatment of adult rat ventricular cardiomyocytes with CsA protected against cell death induced by simulated acute IRI [19]. Griffiths & Halestrap [20] later reported the effects of CsA pre-treatment in isolated perfused rat hearts, observing improved functional recovery and preserved myocardial ATP content following acute MI [20].

The timing of MPTP opening in relation to the onset of ischemia and reperfusion was not known in the early 1990s, and the concept of intervening at the time of reperfusion to target myocardial reperfusion injury was not yet established, and so the MPTP inhibitor had been administered as a pre-treatment in this early study. This all changed in 1995, when Griffith & Halestrap [17] made the crucial discovery that the MPTP remained closed during the index ischemic episode, and only opened in the first 2 to 3 minutes of reperfusion. By measuring the mitochondrial entrapment of titriated glucose, these authors were able to demonstrate that the majority of MPTP opening occurred in the first 2 to 3 minutes of myocardial reperfusion. Despite the presence of MPTP inducers such as calcium, phosphate, oxidative stress and ATP depletion, the intracellular acidic conditions during ischemic inhibit MPTP opening during ischemia. were believed to strongly inhibit MPTP opening during the index ischemia; The intracellular acidic conditions strongly inhibit MPTP opening during the index ischemia, despite the presence of MPTP inducers such as Ca2+, phosphate, oxidative stress and ATP depletion. The rapid restoration of physiological pH in the first couple of minutes of reperfusion then permits the MPTP to open at the onset of reperfusion. A number of studies have used a variety of different methods to confirm that MPTP opening occurs mainly at the onset of reperfusion [21-23].

Several years later in 2002, we confirmed that MPTP opening occurred primarily at the onset of reperfusion by demonstrating that the perfusion of isolated perfused rat hearts with CsA administered solely at the onset of myocardial reperfusion could limit MI size [24]. Crucially, the cardioprotective effects of MPTP inhibition were completely lost if the MPTP inhibitor was administered after the first 15 minutes of myocardial reperfusion had elapsed highlighting the importance of intervening in the first few minutes of reperfusion [8,25]. A number of experimental studies using both *ex vivo* and *in vivo* animal models (murine, rat, rabbit and pig) of acute IRI have confirmed the MI-limiting effects of CsA when administered at the time of myocardial reperfusion, although not all studies have been positive [7]. Gomez and co-workers [26] found that a single bolus of Debio-0125 (a CsA analogue which does not inhibit calcineurin) administered prior to myocardial reperfusion in an *in vivo* murine IRI model had long-term cardioprotective effects including preserved cardiac function and improved survival at 30 days. The obligatory role of the MPTP as a mediator of IRI has been confirmed by genetic studies in 2005, in three independent laboratories who found that mice deficient in mitochondrial CypD (a regulatory component of the MPTP) sustained smaller MI size when compared to wild-type mice [27-29]. Nevertheless, it should be mentioned that there exist other mechanisms of cell death apart from MPTP which are dependent on the duration of ischemia as well as the experimental model used. This was demonstrated in the study of Ruiz-Meana *et al* [30] in which CypD ablation only protected murine cardiomyocytes following 25 minutes of simulated ischemia while no changes in cell death occurring following 15 minutes of simulated ischemia. Similarly, CypD ablation was only able to reduce MI size after 60 minutes ischemia. Interestingly, MI size was actually increased in the CypD-KO mice after 30 min of ischemia. This raised the possibility that after short periods of ischaemia MPTP was not the main cuase of death but this was possibly due to other causes such as hypercontracture [30].

The finding that MPTP opening occurs in the first few minutes of reperfusion [17], has defined a critical time-window for using MPTP inhibition as a cardioprotective strategy. Therefore, any therapeutic strategy that is designed to target myocardial reperfusion injury should be administered either prior to or at the immediate onset of reperfusion in order to prevent MPTP opening occurring [31,32]. The critical timing of the therapeutic intervention has had important implications for the translation of novel cardioprotective therapies into the clinical setting, with studies in which the therapy was administered after reperfusion had already taken place failing to show any benefit [31,32].

1. **The identity of the MPTP**

Despite its initial characterization in the late 1970s and intensive on-going investigation, the molecular identity of the MPTP remains elusive. A variety of different proteins have been postulated to either form the pore component of the MPTP or to regulate its opening.

**5.1. Adenine nucleotide translocase**

From its initial description in the late 1970s [10-12], the adenine nucleotide translocase (ANT) of IMM was thought to form the pore component of the MPTP, given that MPTP opening was sensitive to adenine nucleotides. However, in 2004, Kokoszka *et al* [33] demonstrated that murine liver mitochondria deficient in ANT-1 or ANT-2 still exhibited CsA-sensitive MPTP opening, suggesting that the ANT was unlikely to be the obligatory pore component of the MPTP, and was more likely to act as a modulator of MPTP opening.

**5.2. Voltage-dependent anion channel**

The voltage-dependent anion channel (VDAC) of the OMM had long been considered to be a component of the MPTP [34,35], with the suggestion that the MPTP formed at contact sites between the VDAC of the outer mitochondrial membrane (OMM) and the ANT of the IMM[16]. However, in 2007, Baines *et al* [36] found that murine liver mitochondria deficient in VDAC-1, VDAC-2 or VDAC-3 still displayed CsA-sensitive MPTP opening, suggesting that VDAC may not be an obligatory component of the MPTP.

**5.3. Cyclophilin-D**

The finding in 1988 by Crompton’s research group that MPTP opening could be inhibited by the immunosuppressant, CsA [37], provided initial evidence that the mitochondrial target of CsA may be mitochondrial cyclophilin-D (CypD), a peptidylprolyl *cis-trans* isomerase (reviewed in [7]). Experimental studies by Halestrap’s group in the 1990s provided confirmatory evidence that CypD was an important regulatory component of the MPTP [38,39]. Genetic evidence for this role was published in a collection of studies in 2005 [27-29] which demonstrated that cardiac mitochondria deficient in CypD were resistant to MPTP opening and the hearts were protected against acute IRI.

**5.4. Mitochondrial phosphate carrier**

The mitochondrial phosphate carrier (PiC) mediates the import of inorganic phosphate across the IMM and into the matrix, making it critical for ATP synthesis. Several lines of experimental evidence had implicated the PiC as the potential pore-forming components of the MPTP: (1) From its initial characterization the MPTP has been known to be sensitive to phosphate [13]; (2) The PiC has been shown to form non-specific channels in lipid membranes [40]; (3) There appears to be a direct interaction between PiC and CypD [41].

However, experimental studies have shown that siRNA knockdown of PiC in HeLa cells did not affect MPTP opening susceptibility[42]. Genetic over-expression of cardiac-specific PiC also failed to affect MPTP opening in isolated mitochondria [41]. In addition, cardiac-specific genetic deletion of PiC did not abolish MPTP opening, although it did reduce the sensitivity to MPTP opening and protect hearts from acute IRI, suggesting that although the PiC may not be the obligatory pore-forming component of the MPTP it appears to modulate MPTP function [43]. Interestingly, the genetic ablation of cardiac-specific PiC did result in a hypertrophic cardiomyopathy, consistent with the important role of PiC in maintain normal cardiac function.

**5.5. Mitochondrial ATP synthase**

The mitochondrial ATP synthase or complex V of the electron transport chain plays an essential role in ATP production by coupling the movement of protons from the inter-membranous space into the matrix with the oxidative phosphorylation of ADP. Emerging studies suggest that the ‘*c*’ subunit of the mitochondrial ATP synthase may actually form the IMM pore-forming component of the MPTP. The F1F0 ATP synthase is composed of the catalytic part (F1), comprising a rotor which drives protons into the matrix from the inter-membranous space, and the inner membranous part (F0), which are linked together by central and lateral stalks. In 2009, Giorgio *et al* [44] demonstrated in bovine cardiac mitochondria that CypD was able to bind to the lateral stalk of the Fo ATP synthase, an interaction which was favored by inorganic phosphate and counteracted by CsA.

In a subsequent study, Bonora *et al* [45] demonstrated in HeLa cells that the *c*-subunit of FoATP synthase is required for calcium-induced MPTP opening, as ablation of the *c*-subunit was shown to protect against MPTP opening, whereas the over-expression of the *c*-subunit increased calcium-induced MPTP opening susceptibility. Subsequent studies have suggested that dimers of the F1F0 ATP synthase incorporated into lipid bilayers were able to form calcium-activated channels with features similar to the MPTP [46,47].

Alavian *et al* [48] has proposed a mechanism through which the ATP synthase forms the pore component of the MPTP. They have demonstrated that the purified reconstituted *c*-subunit ring of the F1F0 ATP synthase forms a voltage-sensitive channel, the opening of which results in rapid mitochondrial membrane depolarization [49]. Prolonged high matrix Ca2+ loading was shown to enlarge the *c*-subunit ring and dissociate it from CypD/CsA binding sites in the ATP synthase F1, providing a potential mechanism for MPTP opening [49]. Whether, the molecular identity of the pore-forming component of the MPTP turns out to be the *c*-subunit of mitochondrial ATP synthase needs to be confirmed in further experimental studies, and requires genetic evidence supporting this role.

**5.6. The Bax/Bak proteins**

The pro-apoptotic factors have previously been reported to associate with putative components of the MPTP such as ANT and VDAC [50-52], although subsequent studies have excluded these mitochondrial proteins as obligatory components of the MPTP [33,36]. Most recently, Molkentin’s laboratory [53] have suggested that Bax/Bak by regulating OMM permeability are required for MPTP-dependent necrotic cell death. Interestingly, this role of Bax/Bak was found to be independent on their ability to oligomerize, a property critical for their role in inducing apoptotic cell death.

1. **The MPTP as target for ischemic conditioning**

Ischemic conditioning describes the cardioprotective effect elicited by applying one or more brief cycles of non-lethal ischemia and reperfusion to either the heart itself (direct myocardial conditioning) [54] or to an organ or tissue remote from the heart (termed ‘remote ischemic conditioning’ [RIC]) [55,56]. Experimental studies have demonstrated that MPTP opening is inhibited at the onset of reperfusion in hearts subjected to either ischemic preconditioning (IPC, in which the heart is subjected to one of more brief cycles of ischemia and reperfusion prior to the index ischemia) [24,57-59] or ischemic postconditioning (IPost, in which myocardial reperfusion following the index ischemic event is interrupted by several short-lived episodes of myocardial ischemia) [60,61]. Whether RIC can also inhibit MPTP opening in the heart at the time of reperfusion remains to be determined.

The actual mechanisms through which ischemic conditioning prevents MPTP opening at the time of reperfusion is not clear, although two general pathways have been proposed (which are not mutually exclusive) [62]. In the first proposal, termed ‘indirect MPTP inhibition’, ischemic conditioning modulates factors such as oxidative stress, mitochondrial calcium and phosphate accumulation, ADP/ATP levels and intracellular pH, all of which are known to impact on MPTP opening at the time of reperfusion. In contrast, the second proposal, termed ‘direct MPTP inhibition’ postulates that the activation of known signaling mediators of ischemic conditioning are able to modulate MPTP opening susceptibility by interacting directly with components of the MPTP.

**6.1. Indirect MPTP inhibition by ischemic conditioning**

**6.1.1. Mitochondrial Ca2+and MPTP opening**

Cytosolic and subsequent mitochondrial Ca2+ overload during acute myocardial ischemia is believed to prime the MPTP to open at the onset of myocardial reperfusion [63]. In the first few minutes of reperfusion further mitochondrial Ca2+ accumulation occurs via 2 potential mechanisms precipitating MPTP opening at this time. Firstly, the re-energization of the electron transport chain and the restoration of the mitochondrial membrane potential drives calcium entry into mitochondria via the Ca2+uniporter [63]. Secondly, rapid Ca2+ oscillations between the sarcoplasmic reticulum and mitochondria also results in mitochondrial Ca2+ overload [64]. Given the important role for mitochondrial Ca2+ overload to induce MPTP opening at the onset of reperfusion, several studies have investigated whether effect ischemic conditioning can attenuate cytosolic and mitochondrial Ca2+ overload during acute IRI. Early studies had suggested that IPC through the opening of the ATP-dependent mitochondrial potassium channel (MitoKATP) may reduce mitochondrial Ca2+ overload by causing partial depolarization of the mitochondrial membrane potential [22,65,66]. However, whether MitoKATP channel opening can actually induce sufficient mitochondrial membrane depolarization to reduce mitochondrial Ca2+ accumulation has been questioned [22,67]. Furthermore, the contribution of MitoKATP channels to IPC-protection is still controversial [68,69]. Recently, the individual contribution of mitochondrial Ca2+ overload to MPTP opening at the time of reperfusion has been questioned with studies suggesting that oxidative stress and restoration of physiological pH may be more important inducers of MPTP opening in the setting of acute IRI [63,70]. Furthermore, genetic ablation of the recently discovered mitochondrial calcium uniporter (MCU) was shown to reduce the sensitivity to calcium-induced MPTP opening but did not appear to have any effect on the susceptibility of the heart to acute IRI [71]. A recent study has also implicated CypD in mediating Ca2+ transfer from the ER to the mitochondria via the VDAC1/Grp75/IP3R1 complex. Similar to the inhibition of CypD or any of the components in this complex, down-regulation of Mfn2 reduces the interaction between CypD and the complex thus reducing mitochondrial Ca2+ overload and cardiac cell death. Whether ischemic conditioning actually affects the interaction of CypD with this complex remains to be elucidated [72].

**6.1.2. Mitochondrial reactive oxygen species and MPTP opening**

The production of oxidative stress from the re-energized electron transport chain in the first few minutes of myocardial reperfusion is believed to be a major factor for inducing MPTP opening at the onset of reperfusion. Several experimental studies have demonstrated that both IPC [73-77], and IPost [60,78] attenuates the production of oxidative stress at the time of reperfusion although this beneficial effect has not yet been directly linked to MPTP inhibition. The actual mechanism through which IPC and IPost actually attenuate oxidative stress at the time of reperfusion is not known. Halestrap’s group has postulated that the loss of mitochondrial cytochrome *c* into the cytosol during acute myocardial ischemia inhibits mitochondrial respiration resulting in the production of oxidative stress and subsequent MPTP opening at the time of reperfusion [79]. The authors have suggested that IPC preserves the integrity of the OMM, thereby preventing loss of cytochrome *c* into the cytosol thereby attenuating the production of oxidative stress and MPTP opening at reperfusion [79]. More recently, Murphy’s group has suggested an alternative hypothesis to explain the burst of oxidative stress which occurs at the onset of reperfusion. They have shown that ischemia results in the myocardial accumulation of the mitochondrial complex II substrate succinate, which at the onset of reperfusion then provides a substrate load to complex II which via reverse electron transport feeds through to complex I, generating the oxidative stress observed in the first few minutes of reperfusion [80]. Whether IPC confers its cardioprotective effect by attenuating the ischemia-induced accumulation of succinate, and IPost does so by antagonizing the production of oxidative stress from complex I at the onset of reperfusion would be interesting to investigate.

**6.1.3. Cellular energy status and MPTP opening**

In the original study which first discovered IPC [57], the authors had proposed that the preservation of myocardial ATP levels may be critical to the cardioprotection elicited by IPC. Later studies have demonstrated that IPC protects by reducing ATP consumption during myocardial ischemia [81-83] and preserving mitochondrial energy production during acute IRI [83-86], effects which have not yet shown to directly inhibit MPTP opening at reperfusion. Following the possible identification of the mitochondrial ATP synthase as the MPTP, Murphy and Steenbergen [87] have raised the intriguing possibility that the early observation of IPC preventing ATP depletion during acute myocardial ischemia may relate to IPC-induced inhibition of mitochondrial ATP synthase activity.

**6.1.4. Intracellular pH and MPTP opening**

The rapid restoration of physiological intracellular pH in the first few minutes of myocardial reperfusion, from the acidic pH induced by acute myocardial ischemia, is believed to precipitate MPTP opening at this time. Recent studies have suggested that IPC and IPost may inhibit MPTP opening at the time of reperfusion by delaying the restoration of physiological pH, although the mechanism through which this is achieved in not clear [88]. Prior experimental studies had reported that IPC attenuated the intracellular acidosis generated during acute myocardial ischemia [82,89,90], an effect which was attributed to myocardial glycogen depletion, reducing the substrate supply for anerobic glycolysis, resulting in less myocardial lactate accumulation during acute myocardial ischemia [89,91]. IPC has also been reported to inhibit the activity of the NHE at the time of myocardial reperfusion as a mechanism for slowing the restoration of normal pH and reducing intracellular sodium and calcium accumulation at this time [92,93], although at the time this finding was controversial [94]. In this respect, the recent finding that the pro-survival protein kinase, Akt, which has been implicated as a critical mediator that comes into play at the time of reperfusion in the settings of both IPC, has been demonstrated to inhibit the activity of the NHE at this time [95], is an interesting possibility.

With respect to IPost, Hori *et al* [96] first demonstrated in 1991 that intermittent reperfusion induced transient acidosis and ameliorated myocardial stunning. Subsequent studies have confirmed that IPost exerts its cardioprotective effect by preventing the washout of myocardial lactate thereby maintaining the acidic environment in the reperfused heart, and inhibiting MPTP opening and allowing the activation of pro-survival kinases such as Akt and Erk1/2 (pH hypothesis) [88,97]. Whether, the delayed restoration of physiological pH by IPost results in MPTP inhibition at the time of reperfusion remains to be shown directly.

**6.2. Direct MPTP inhibition by ischemic conditioning**

Both IPC and IPost are known to protect the heart through the activation of a variety of specific signaling cascades many of which terminate on mitochondria and mediate the inhibition of MPTP opening at the time of reperfusion.

**The RISK and SAFE pathway and the MPTP**

It is well-established that the acute activation of cardioprotective protein kinase pathways (such as the Reperfusion Injury Salvage Kinase [RISK] and the Survival Activation Factor Enhancement [SAFE]) at the onset of myocardial reperfusion, can limit MI size [98-101]. Crucially, ischemic conditioning has been reported to recruit these salvage kinase pathways at the onset of reperfusion and there is evidence linking these pathways to MPTP inhibition [102,103].

**6.2.1. The RISK pathway and the MPTP**

All 3 forms of ischemic conditioning (IPC, IPost and RIC) has been linked to the activation of the RISK pathway and in the cases of IPC and IPost the activation of this salvage kinase pathway has been shown to inhibit MPTP opening inhibition [102-105]. The actual mechanism through which RISK pathway activation mediates it inhibitory effect on MPTP opening is unclear and it may do this through the activation of a downstream mediator such as PKG, GSK-3β, or Hexokinase II, or it may be through the modification of MPTP induction factors such as oxidative stress, calcium or pH correction.

Experimental data has suggested that salvage kinases of the RISK pathway such as Akt [106], Erk1/2 [107] and PKG [108] may translocate to mitochondria and in some cases the mitochondrial translocation has been linked to MPTP inhibition, although the actual mechanism thorough which these cytosolic kinases are able to access the inner membrane components of the MPTP are not known. One experimental study has questioned the link between these cardioprotective kinases translocating to mitochondria and MPTP inhibition citing indirect effects of IPC on attenuating oxidative stress as the mechanism of MPTP inhibition [77]. Potential downstream targets of the Akt and Erk1/2 components of the RISK pathway which have been linked to MPTP inhibition include PKG, GSK-3β, and hexokinase II.

*PKG and the MPTP*

The activation of the Akt component of the RISK pathway is known to recruit the eNOS-NO-cGMP-PKG pathway and through this cascade [109], the RISK pathway may inhibit MPTP opening. This pathway appears to be mediated through the translocation of PKG to the OMM where it is believed to phosphorylate mitochondrial PKC-ε and result in MPTP inhibition via the MitoKATP channel (see section 4.2.1) [109]. Whether this actual signaling pathway is in operation during the first few minute of reperfusions is not known and has not been directly demonstrated for either IPC or IPost.

*GSK-3β and the MPTP*

An important downstream target of the Akt and Erk1/2 components of the RISK pathway is glycogen synthase kinase-3β (GSK-3β), a protein kinase which regulates a variety of cellular processes including apoptosis, growth and metabolism [110]. Phosphorylation and inactivation of GSK-3β has been linked to cardioprotection by IPC and IPost [111,112], although not all studies have been in agreement [113].

In a cardiomyocyte model of oxidative stress, Sollott’s research group [114] provided comprehensive *in vitro* evidence suggesting that the phosphorylation and inactivation of mitochondrial GSK-3β with MPTP inhibition was the underlying mechanism for a diverse array of cardioprotective strategies. However, the mechanism through which mitochondrial GSK-3β inhibition actually mediates MPTP inhibition is unclear. Nishihara *et al* [115] have reported that GSK-3β associated with ANT in IPC-treated hearts, but this data no longer implicates the MPTP given that ANT is no longer considered to be an essential component of the MPTP [33]. GSK-3β inhibition has also been suggested to, allow the dephosphorylation of the OMM protein, VDAC, which prevents the entry of adenine nucleotides into mitochondria, which would be expected to facilitate mitochondrial depolarization and reduce mitochondrial calcium accumulation and ROS production during myocardial ischemia thereby preventing MPTP opening at the time of reperfusion [116]. A more recent study has also demonstrated that the translocation of GSK-3β from the cytosol to mitochondria is a kinase activity- and VDAC2-dependent process in which an N-terminal domain of GSK-3β may help target the protein to mitochondria [117]. Whether this mechanism actually operates in the setting of IPC and IPost remains to be investigated.

*Hexokinase II and the MPTP*

Another downstream mediator of the Akt component of the RISK pathway is the glycolytic enzyme hexokinase II (HK II), the mitochondrial translocation of which has been implicated in IPC cardioprotection (reviewed in [118]). A variety of different mechanisms have been proposed for the cardioprotective effect of mitochondrial HK II including the maintenance of OMM permeability during IRI (stabilizing the ΔΨm and preventing OMM rupture and the release of cytochrome C), attenuating ROS production, improved glucose-induced insulin release, prevention of acidosis through enhanced coupling of glycolysis and glucose oxidation, and inhibition of fatty acid oxidation (as reviewed in [119]).

**6.2.2. The SAFE pathway and the MPTP**

Recruitment of the Survivor Activating Factor Enhancement (SAFE) pathway at the time of reperfusion, which includes the components tumor necrosis factor alpha (TNFα) and the signal transducer and activator of transcription 3 (STAT-3), has been associated with cardioprotection from both IPC and IPost [100,120-122]. The activation of the SAFE pathway at the onset of reperfusion has also been linked to MPTP inhibition [123,124], although the mechanism for this effect is not clear. Recent experimental data has suggested that STAT3 may actually reside in the mitochondria [125], but the mechanism through which it inhibits MPTP opening is not known. Again whether this pathway operates at reperfusion in the setting of IPC or IPost has not been investigated.

**6.2.3. Mitochondrial morphology and the MPTP**

Mitochondria are dynamic structures capable of changing their morphology by undergoing either fusion to generate an elongated phenotype (regulated by the mitochondrial fusion proteins [Mitofusins and OPA1]) or fission to form fragmented mitochondria (regulated by the mitochondrial fission proteins [Drp1, hFis1]) [126-129]. Recent experimental data suggests that mitochondria undergo fission and MPTP opening in response to acute IRI, and genetic or pharmacological inhibition of mitochondrial fission has been reported to inhibit MPTP opening and to attenuate cell death [130]. These findings suggested a link between mitochondrial morphology and MPTP opening susceptibility, with inhibiting mitochondrial fission induced by acute IRI appearing to prevent MPTP opening at the time of reperfusion.

Interestingly, some of the cardioprotective kinases which have been linked to MPTP inhibition in the setting of ischemic conditioning such as PKA and Akt have been reported to modulate mitochondrial morphology through the phosphorylation of Drp1 [131,132] and OPA1 [133], respectively. A recent experimental study has shown that pharmacological preconditioning with nitrites has been shown to inhibit mitochondrial fission through PKA-induced phosphorylation and inhibition of Drp1 [134]. Whether ischemic conditioning also protects the heart against acute IRI by inhibiting mitochondrial fission and MPTP inhibition remains to be investigated.

**6.2.4. Modification of CypD and the MPTP**

There is strong pharmacological and genetic evidence confirming mitochondrial CypD to be an important regulatory component of the MPTP. The current paradigm suggests that at reperfusion, CypD associates with the pore-component of the MPTP and mediates a conformation change of this protein into the non-selective pore of the MPTP. Therefore, ischemic conditioning may affect MPTP opening susceptibility by modulating CypD activity. In this regard, CypD may be amenable to post-translational modification by oxidation, s-nitrosylation, acetylation and so forth. In terms of ischemic conditioning, it has been shown that preconditioning by rapid cardiac pacing in a canine heart inhibited calcium-induced MPTP opening in isolated mitochondria, and this was associated with a more oxidative environment promoted by the decreased mitochondrial GSH/GSSG ratio, resulting in increased S-glutathionylation of CypD, thereby possibly inhibiting its ability to induce MPTP opening [135].

1. **A protective form of MPTP opening?**

Sustained opening of the MPTP in the first few minutes of reperfusion is a critical determinant of cardiomyocyte death, and suppressing its opening at this time will rescue viable myocardium from acute IRI. However, there exists another form of MPTP, which is transient and reversible and may occur under non-pathological conditions [136]. This form of MPTP opening or MPTP ‘flickering’ has been associated with the release of ROS and calcium and may contribute to its physiological role [137-143].

Several years ago, we investigated the role for transient MPTP opening as a mediator of IPC cardioprotection [136].We discovered that perfusing isolated rat hearts with CsA during the administration of a standard IPC protocol actually blocked the MI-limiting effect of IPC, suggesting that some form of MPTP opening was required to mediate IPC cardioprotection [136]. We also found that the preconditioning mimetic diazoxide could mediate MPTP opening in isolated rat cardiomyocytes as measured by the redistribution of mitochondrial calcein[136]. At the time we postulated that reversible MPTP opening may mediate IPC-cardioprotection by either generating mitochondrial signaling ROS or by acting as a calcium release mechanism for reducing mitochondrial calcium prior to the index ischemic event [136].

More recent studies have begun to unravel the potential physiological roles of the MPTP, suggesting that it may be important in both calcium and energy homeostasis in the cell.

1. **A physiological role for the MPTP?**

Since its initial discovery there has been much speculation over a physiological role for the MPTP. In this regard, recent experimental data have explored the role of the MPTP in calcium and energy homeostasis. However, it must be noted that most of these studies have focused on CypD rather than the actual MPTP itself.

In 1992, Altschuld *et al* [144] first demonstrated that treatment with the MPTP inhibitor, CsA, prevented mitochondrial Ca2+ efflux in adult rat ventricular cardiomyocytes, thereby postulating that the MPTP may mediate mitochondrial calcium efflux. This finding was confirmed by Elrod *et al* [145] who found that mice deficient in CypD were more sensitive to pressure-overload induced hypertrophic cardiomyopathy, findings which were associated with an elevated mitochondrial matrix Ca2+, resulting in increased glucose oxidation compared to fatty acids, thereby limiting the metabolic reserve in response to stress. The changes in cardiac metabolism observed in the CypD-deficient heart have been found to be due the acetylation and inhibition of metabolic enzymes important for fatty acid oxidation [146,147]. Another study has shown the CypD knockout to develop adult-onset obesity secondary to white adipose tissue accumulation, the mechanism for this is not clear but may relate to the metabolic defect previously observed [148]. The group of Ovize [72] recently demonstrated an additional role of CypD in mediating Ca2+ transfer from the ER to the mitochondria via its interaction with the VDAC1/Grp75/IP3R1 complex in cardiomyocytes. The interaction between CypD and these components increases during hypoxia-re-oxygenation and inhibition of either of the components attenuated mitochondrial Ca2+ overload and cell death [72]. Nevertheless, the disruption of the functional domain between the ER and mitochondria has also been implicated in impaired insulin signaling [149]. Therefore, we can postulate that the interaction between CypD and the VDAC1/Grp75/IP3R1 complex may be required for normal homeostatic function of glucose and metabolism but it then becomes deleterious under conditions of stress.

1. **Translating MPTP inhibition into the clinical setting**

**9.1. MPTP as a therapeutic target in the presence of confounding factors**

In order to be a viable therapeutic strategy for cardioprotection in the clinical setting it is essential to demonstrate that it is effective in the presence of confounding factors which are known to interfere with cardioprotection. It is well established in pre-clinical animal IRI studies that the presence of certain co-morbid illnesses such as age, diabetes, hypertension, left ventricular hypertrophy and so forth, and a variety of concomitant medication, may impact on the susceptibility of the heart to ischemic conditioning (reviewed in [150,151]). Therefore, it is important to investigate in appropriately designed animal IRI models whether MPTP inhibition is effective in the presence of co-morbid conditions and concomitant medication. Unfortunately, many of the animal IRI models used in cardioprotection studies fail to take these confounding factors into account in their study design.

Huhn *et al* [152] found that the pre-diabetic normoglycemic Zucker obese rat was resistant to the cardioprotective effects of MPTP inhibition using CsA (at 5 or 10 mg/kg) administered at the onset of myocardial reperfusion. In contrast, in a recently published experimental study, CsA-derived cardioprotection was demonstrated to be preserved in the aged murine heart subjected to acute IRI [153]. Further studies are required to determine whether the presence of other co-morbidities (such as hyperlipdemia and LVH), and concomitant medication (such as beta-blockers, statin therapy) can influence the cardioprotective effect of CsA, and if these findings are confirmed the underlying mechanisms for this interaction need to be explored. It may be surprising that MPTP inhibition using is affected by these confounding factors, given that the MPTP is placed downstream of the cardioprotective signaling pathways known to be affected by these confounding factors. However, perturbation in mitochondrial function and putative components of the MPTP by the presence of co-morbid conditions such as diabetes may impact on the MPTP susceptibility to CsA.

**9.2. MPTP as a therapeutic target in *ex vivo* human heart tissue**

The inhibition of MPTP opening as a therapeutic approach has been reported to be effective in the human heart tissue, an important step in the process for translating cardioprotection into the clinical setting (Table 1). Schneider *et al* [154] found that pre-treatment with CsA protected slices of human right atrial appendage tissue (harvested from CABG patients) against simulated acute IRI [154]. Using human atrial trabeculae and atrial cardiomyocytes (isolated from patient right atrial appendage tissue) subjected to simulated acute IRI, we demonstrated that the administration of CsA at re-oxygenation improved the recovery of baseline contractile function and reduced cell death, respectively [155]. Crucially, we showed delayed MPTP opening in atrial cardiomyocytes pre-treated with CsA [155]. We have recently shown that the MPTP can be inhibited by CsA in ventricular cardiomyocytes harvested from patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy, suggesting that MPTP inhibition is a viable cardioprotective strategy in the presence of hypertrophic cardiomyopathy [156].

**9.3. MPTP inhibition as a therapeutic strategy in the clinical setting**

**9.3.1. MPTP inhibition in patients presenting with an acute myocardial infarction**

The first study to investigate MPTP inhibition as a therapeutic strategy in the clinical setting of acute IRI, was a small proof-of-concept clinical trial by Piot *et al* [157]. Fifty eight patients presenting with an acute STEMI were randomized to receive a single intravenous bolus of either CsA (2.5 mg/kg) or placebo, 10 minutes prior to PPCI. In those patients who received CsA therapy, MI size (measured by the 72 hour area-under-the-curve total creatine kinase) was reduced by 40% when compared to placebo control. In a follow-up study, it was demonstrated that MI size was reduced and there was less adverse left ventricular (LV) remodeling on cardiac MRI scans performed at 5 days and 6 months [158]. It is important to note that in this first clinical study, CsA was administered as a single intravenous bolus prior to myocardial reperfusion, and only patients presenting with a complete acute coronary artery occlusion (pre-PPCI TIMI 0 flow) were eligible for recruitment to ensure reperfusion had not already taken place, key features for optimizing in clinical study design when investigating cardioprotection in the clinical setting [31,32,159].

There are two ongoing large clinical studies investigating whether MPTP inhibition using CsA is beneficial on short-term and long-term clinical outcomes. The CYCLosporinEA in Reperfused Acute Myocardial Infarction (CYCLE) study is a large multicenter randomized 444 patient clinical trial currently investigating the effect of a single bolus of CsA compared to placebo administered prior to PPCI on ST-segment resolution (a marker of myocardial reperfusion) in STEMI patients (ClinicalTrials.gov NCT01650662). The Cyclosporine and Prognosis in Acute Myocardial Infarction Patients (CIRCUS) study is a large 972 STEMI patient multicenter randomized clinical trial investigating the effect of a single bolus of CsA administered prior to PPCI on the one year primary combined endpoint (total mortality, hospitalization for heart failure, and LV remodeling [increase of LV end-diastolic volume>15%]) compared to placebo (ClinicalTrials.gov NCT01502774). These large studies should provide an indication as to whether the presence of co-morbidities such as diabetes, age, hypertension and hypercholesterolemia impact on CsA-derived cardioprotection in the clinical setting. Both these large studies have restricted their recruitment to those patients presenting with fully occluded coronary arteries and large myocardial infarcts, as these patients are those most likely to benefit from CsA therapy. However, STEMI patients presenting with cardiogenic shock were excluded from recruitment in both these studies. In this regard, the Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (CLOTILDE), is a 100 STEMI patient proof-of-concept clinical study which will investigate this therapeutic approach in this high-risk patient group using multi-organ failure as its primary endpoint (ClinicalTrials.gov NCT01901471).

Interestingly, MPTP inhibition as a therapeutic approach did not appear to be beneficial in acute STEMI patients treated by thrombolytic therapy. Ghaffari *et al* [160] found that pre-thrombolytic administration of CsA (2.5 mg/kg) did not reduce MI size (measured by peak serum CK-MB or Troponin-I in first 24 hours) or influence clinical outcome measures. The reason for this discrepant finding is not clear but it may be related to the reperfusion strategy with thrombolytic therapy resulting in gradual reperfusion, which may reduce the magnitude of myocardial reperfusion injury to protect against. In contrast, PPCI may be expected to induce rapid abrupt reperfusion, which may paradoxically increase the extent of reperfusion injury.

**9.3.2. MPTP inhibition in patients undergoing cardiac bypass surgery**

For patients with multi-vessel coronary artery disease the treatment of choice is coronary revascularization by coronary artery bypass graft (CABG) surgery. During cardiac bypass surgery, the heart is subjected to acute global ischemia and reperfusion injury, as the heart is put onto and taken off cardiopulmonary bypass, respectively. The extent of peri-operative myocardial injury (PMI), which can be quantified by measuring the release of serum cardiac enzymes such as CK-MB and Troponin T or I, has been linked to worse clinical outcomes post-surgery. We have recently investigated MPTP inhibition as a therapeutic approach in adult patients undergoing CABG surgery [161]. We found that the administration of a single dose of CsA (2.5 mg/kg) prior to surgical incision reduced the extent of PMI (measured by the peak Troponin T over 72 hours) in those patients with longer cardiopulmonary bypass times (>85 minutes), when compared to placebo control [161]. Importantly, there were no reported adverse effects on renal or liver function [161]. The cardioprotective effects of MPTP inhibition by CsA in the setting of cardiac bypass surgery has been confirmed in patients undergoing aortic valve surgery, in which CsA was found to be more effective than the former study as it reduced the extent of PMI by 35% [162]. One important reason for this difference may be that the intravenous bolus of CsA was administered prior to reperfusion at the time of declamping the aorta in this study whereas in the former study CsA was given prior to surgical incision [161,162].

**9.3.3. MPTP inhibition in other clinical settings**

For patients having a cardiac arrest, the heart is subjected to acute global myocardial ischemic injury, and the restoration of spontaneous circulation from successful cardiopulmonary resuscitation then subjects the heart to acute global myocardial reperfusion injury. In pre-clinical animal models of successful cardiac arrest, MPTP inhibition using CsA as a therapeutic intervention has been demonstrated to preserve myocardial function and reduce myocardial injury [163,164]. Whether administering an intravenous bolus of CsA to inhibit MPTP opening is beneficial in patients presenting with a cardiac arrest remains to be investigated.

In patients undergoing cardiac transplantation, the donor heart is subjected to acute global ischemic injury followed by acute global reperfusion injury when it is implanted into the recipient patient. Whether MPTP inhibition can prevent acute myocardial IRI and preserve myocardial function in the pre-clinical or clinical setting of cardiac transplantation is not known.

In non-cardiac clinical settings of acute IRI such as patients treated by thrombolytic therapy for an acute ischemic stroke, in patients undergoing organ transplantation and so on may also be amenable to MPTP inhibition as a therapeutic strategy for protection against acute IRI.

**9.4. The need for more specific MPTP inhibitors**

Because CsA is not a specific inhibitor of MPTP and inhibits calcineurin and other cyclophilins, more specific MPTP inhibitors need to be discovered if MPTP inhibition is going to be widely used as a therapeutic approach to cardioprotection (reviewed in [7]). Amidst attempts to get round the problems with CsA, there exist alternative choices of CsA analogues which do not inhibit calcineurin [165,166] and potential of modifying the structure of CsA to make it more selective for mitochondrial CypD [167]. Finally, there are several new drugs currently under investigation such as TRO4303 [168] and Bendavia which have been reported to reduce MI size by inhibiting the MPTP, although there is no evidence suggesting that these drugs are able to inhibit MPTP opening is isolated mitochondria. A recent clinical study failed to reduce MI size with TRO40303 administered to STEMI patients prior to PPCI to prevent myocardial reperfusion injury [169]. The identification of the pore-component of the MPTP should facilitate the discovery of novel more specific MPTP inhibitors.

1. **Summary and Conclusions**

The MPTP is a critical mediator of cardiomyocyte death in the setting of acute IRI, opening in the first few minutes of myocardial reperfusion, and contributing up to 50% of the final infarct size. As such, it is an important target for cardioprotection, and MPTP inhibition using CsA has been shown to limit MI size in both animal studies and clinical studies of acute IRI (as shown in Table 1). MPTP inhibition at the time of reperfusion has also been demonstrated to be the main effector of cardioprotective signaling cascades underlying ischemic conditioning, although the mechanisms mediating this inhibitory effect on MPTP opening are unclear. The molecular identity of the pore-component of the MPTP remains unknown although recent data suggests it may be the c-subunit of the mitochondrial ATPase. However, further experimental and genetic studies are required to confirm this finding. Finally, given that CsA is not a specific inhibitor of the MPTP, novel more specific and potent inhibitors of the MPTP need to be discovered in order to translate MPTP inhibition into the clinical setting as a viable cardioprotective strategy so that clinical outcomes for patients with IHD can be improved.

**Acknowledgments**

S.-B. Ong was funded by a Dorothy Hodgkin Postgraduate Award (Biotechnology and Biological Sciences Research Council). We thank the British Heart Foundation for their continued support FS/10/039/28270 and FS/13/41/30368). This work was undertaken at University College London Hospital/University College London, which received a portion of funding from the Department of Health’s National Institute of Health Research Biomedical Research Centres funding scheme.

**Conflict of Interest:** None

**REFERENCES**

 1. Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM. 2013. National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010. Circulation 128: 2577-2584.

 2. Yellon DM, Hausenloy DJ. 2007. Myocardial reperfusion injury. N Engl J Med 357: 1121-1135.

 3. Hausenloy DJ, Yellon DM. 2013. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123: 92-100.

 4. Hausenloy DJ, Yellon DM. 2003. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35: 339-341.

 5. Hausenloy DJ, Ong SB, Yellon DM. 2009. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 104: 189-202.

 6. Di LF, Carpi A, Giorgio V, Bernardi P. 2011. The mitochondrial permeability transition pore and cyclophilin D in cardioprotection. Biochim Biophys Acta 1813: 1316-1322.

 7. Hausenloy DJ, Boston-Griffiths EA, Yellon DM. 2012. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 165: 1235-1245.

 8. Halestrap AP, Richardson AP. 2014. The mitochondrial permeability transition: A current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol.

 9. Hunter DR, Haworth RA, Southard JH. 1976. Relationship between configuration, function, and permeability in calcium-treated mitochondria. J Biol Chem 251: 5069-5077.

 10. Hunter DR, Haworth RA. 1979. The Ca2+-induced membrane transition in mitochondria. I. The protective mechanisms. Arch Biochem Biophys 195: 453-459.

 11. Hunter DR, Haworth RA. 1979. The Ca2+-induced membrane transition in mitochondria. III. Transitional Ca2+ release. Arch Biochem Biophys 195: 468-477.

 12. Haworth RA, Hunter DR. 1979. The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys 195: 460-467.

 13. Al Nasser I, Crompton M. 1986. The reversible Ca2+-induced permeabilization of rat liver mitochondria. Biochem J 239: 19-29.

 14. Crompton M, Costi A, Hayat L. 1987. Evidence for the presence of a reversible Ca2+-dependent pore activated by oxidative stress in heart mitochondria. Biochem J 245: 915-918.

 15. Crompton M, Costi A. 1988. Kinetic evidence for a heart mitochondrial pore activated by Ca2+, inorganic phosphate and oxidative stress. A potential mechanism for mitochondrial dysfunction during cellular Ca2+ overload. Eur J Biochem 178: 489-501.

 16. Crompton M, Virji S, Doyle V, Johnson N, Ward JM. 1999. The mitochondrial permeability transition pore. Biochem Soc Symp 66: 167-179.

 17. Griffiths EJ, Halestrap AP. 1995. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307 ( Pt 1): 93-98.

 18. Bernardi P, Vassanelli S, Veronese P, Colonna R, Szabo I, Zoratti M. 1992. Modulation of the mitochondrial permeability transition pore. Effect of protons and divalent cations. J Biol Chem 267: 2934-2939.

 19. Nazareth W, Yafei N, Crompton M. 1991. Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A. J Mol Cell Cardiol 23: 1351-1354.

 20. Griffiths EJ, Halestrap AP. 1993. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 25: 1461-1469.

 21. Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P. 2001. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276: 2571-2575.

 22. Murata M, Akao M, O'Rourke B, Marban E. 2001. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res 89: 891-898.

 23. Matsumoto-Ida M, Akao M, Takeda T, Kato M, Kita T. 2006. Real-time 2-photon imaging of mitochondrial function in perfused rat hearts subjected to ischemia/reperfusion. Circulation 114: 1497-1503.

 24. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. 2002. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55: 534-543.

 25. Hausenloy DJ, Duchen MR, Yellon DM. 2003. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60: 617-625.

 26. Gomez L, Thibault H, Gharib A, Dumont JM, Vuagniaux G, Scalfaro Pet al. 2007. Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am J Physiol Heart Circ Physiol 293: H1654-H1661.

 27. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. 2005. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 280: 18558-18561.

 28. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MAet al. 2005. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434: 658-662.

 29. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata Het al. 2005. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434: 652-658.

 30. Ruiz-Meana M, Inserte J, Fernandez-Sanz C, Hernando V, Miro-Casas E, Barba Iet al. 2011. The role of mitochondrial permeability transition in reperfusion-induced cardiomyocyte death depends on the duration of ischemia. Basic Res Cardiol 106: 1259-1268.

 31. Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey Jet al. 2010. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 105: 677-686.

 32. Hausenloy DJ, Erik BH, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch Get al. 2013. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 98: 7-27.

 33. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DPet al. 2004. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427: 461-465.

 34. Szabo I, De P, V, Zoratti M. 1993. The mitochondrial permeability transition pore may comprise VDAC molecules. II. The electrophysiological properties of VDAC are compatible with those of the mitochondrial megachannel. FEBS Lett 330: 206-210.

 35. Szabo I, Zoratti M. 1993. The mitochondrial permeability transition pore may comprise VDAC molecules. I. Binary structure and voltage dependence of the pore. FEBS Lett 330: 201-205.

 36. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. 2007. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol 9: 550-555.

 37. Crompton M, Ellinger H, Costi A. 1988. Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 255: 357-360.

 38. Halestrap AP, Davidson AM. 1990. Inhibition of Ca2(+)-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J 268: 153-160.

 39. Griffiths EJ, Halestrap AP. 1991. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. Biochem J 274 ( Pt 2): 611-614.

 40. Gutierrez-Aguilar M, Perez-Martinez X, Chavez E, Uribe-Carvajal S. 2010. In Saccharomyces cerevisiae, the phosphate carrier is a component of the mitochondrial unselective channel. Arch Biochem Biophys 494: 184-191.

 41. Gutierrez-Aguilar M, Douglas DL, Gibson AK, Domeier TL, Molkentin JD, Baines CP. 2014. Genetic manipulation of the cardiac mitochondrial phosphate carrier does not affect permeability transition. J Mol Cell Cardiol 72: 316-325.

 42. Varanyuwatana P, Halestrap AP. 2012. The roles of phosphate and the phosphate carrier in the mitochondrial permeability transition pore. Mitochondrion 12: 120-125.

 43. Kwong JQ, Davis J, Baines CP, Sargent MA, Karch J, Wang Xet al. 2014. Genetic deletion of the mitochondrial phosphate carrier desensitizes the mitochondrial permeability transition pore and causes cardiomyopathy. Cell Death Differ 21: 1209-1217.

 44. Giorgio V, Bisetto E, Soriano ME, Dabbeni-Sala F, Basso E, Petronilli Vet al. 2009. Cyclophilin D modulates mitochondrial F0F1-ATP synthase by interacting with the lateral stalk of the complex. J Biol Chem 284: 33982-33988.

 45. Bonora M, Bononi A, De ME, Giorgi C, Lebiedzinska M, Marchi Set al. 2013. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. Cell Cycle 12: 674-683.

 46. Giorgio V, von SS, Antoniel M, Fabbro A, Fogolari F, Forte Met al. 2013. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci U S A 110: 5887-5892.

 47. Carraro M, Giorgio V, Sileikyte J, Sartori G, Forte M, Lippe Get al. 2014. Channel formation by yeast F-ATP synthase and the role of dimerization in the mitochondrial permeability transition. J Biol Chem 289: 15980-15985.

 48. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park HA, Licznerski Pet al. 2014. An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. Proc Natl Acad Sci U S A 111: 10580-10585.

 49. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park HA, Licznerski Pet al. 2014. An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. Proc Natl Acad Sci U S A 111: 10580-10585.

 50. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HLet al. 1998. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281: 2027-2031.

 51. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda Het al. 1998. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A 95: 14681-14686.

 52. Shimizu S, Narita M, Tsujimoto Y. 1999. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-487.

 53. Karch J, Kwong JQ, Burr AR, Sargent MA, Elrod JW, Peixoto PMet al. 2013. Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice. Elife 2: e00772.

 54. Hausenloy DJ. 2013. Cardioprotection techniques: preconditioning, postconditioning and remote con-ditioning (basic science). Curr Pharm Des 19: 4544-4563.

 55. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. 1993. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87: 893-899.

 56. Hausenloy DJ, Yellon DM. 2008. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 79: 377-386.

 57. Murry CE, Jennings RB, Reimer KA. 1986. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136.

 58. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. 2003. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 549: 513-524.

 59. Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR. 2004. Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 287: H841-H849.

 60. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RAet al. 2003. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579-H588.

 61. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. 2005. Postconditioning inhibits mitochondrial permeability transition. Circulation 111: 194-197.

 62. Hausenloy DJ, Ong SB, Yellon DM. 2009. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol.

 63. Ruiz-Meana M, Garcia-Dorado D, Miro-Casas E, Abellan A, Soler-Soler J. 2006. Mitochondrial Ca(2+) uptake during simulated ischemia does not affect permeability transition pore opening upon simulated reperfusion. Cardiovasc Res 71: 715-724.

 64. Ruiz-Meana M, Abellan A, Miro-Casas E, Agullo E, Garcia-Dorado D. 2009. Role of sarcoplasmic reticulum in mitochondrial permeability transition and cardiomyocyte death during reperfusion. Am J Physiol Heart Circ Physiol 297: H1281-H1289.

 65. Crestanello JA, Doliba NM, Babsky AM, Doliba NM, Niibori K, Osbakken MDet al. 2000. Opening of potassium channels protects mitochondrial function from calcium overload. J Surg Res 94: 116-123.

 66. Wang L, Cherednichenko G, Hernandez L, Halow J, Camacho SA, Figueredo Vet al. 2001. Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels. Am J Physiol Heart Circ Physiol 280: H2321-H2328.

 67. Garlid KD. 2000. Opening mitochondrial K(ATP) in the heart--what happens, and what does not happen. Basic Res Cardiol 95: 275-279.

 68. Hanley PJ, Daut J. 2005. K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J Mol Cell Cardiol 39: 17-50.

 69. Ardehali H, O'Rourke B. 2005. Mitochondrial K(ATP) channels in cell survival and death. J Mol Cell Cardiol 39: 7-16.

 70. Kim JS, Jin Y, Lemasters JJ. 2006. Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 290: H2024-H2034.

 71. Pan X, Liu J, Nguyen T, Liu C, Sun J, Teng Yet al. 2013. The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol 15: 1464-1472.

 72. Paillard M, Tubbs E, Thiebaut PA, Gomez L, Fauconnier J, Da Silva CCet al. 2013. Depressing mitochondria-reticulum interactions protects cardiomyocytes from lethal hypoxia-reoxygenation injury. Circulation 128: 1555-1565.

 73. Tosaki A, Cordis GA, Szerdahelyi P, Engelman RM, Das DK. 1994. Effects of preconditioning on reperfusion arrhythmias, myocardial functions, formation of free radicals, and ion shifts in isolated ischemic/reperfused rat hearts. J Cardiovasc Pharmacol 23: 365-373.

 74. Crestanello JA, Lingle DM, Kamelgard J, Millili J, Whitman GJ. 1996. Ischemic preconditioning decreases oxidative stress during reperfusion: a chemiluminescence study. J Surg Res 65: 53-58.

 75. Vanden Hoek T, Becker LB, Shao ZH, Li CQ, Schumacker PT. 2000. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ Res 86: 541-548.

 76. Raphael J, Drenger B, Rivo J, Berenshtein E, Chevion M, Gozal Y. 2005. Ischemic preconditioning decreases the reperfusion-related formation of hydroxyl radicals in a rabbit model of regional myocardial ischemia and reperfusion: the role of K(ATP) channels. Free Radic Res 39: 747-754.

 77. Clarke SJ, Khaliulin I, Das M, Parker JE, Heesom KJ, Halestrap AP. 2008. Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation. Circ Res 102: 1082-1090.

 78. Sun HY, Wang NP, Kerendi F, Halkos M, Kin H, Guyton RAet al. 2005. Hypoxic postconditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca2+ overload. Am J Physiol Heart Circ Physiol 288: H1900-H1908.

 79. Pasdois P, Parker JE, Griffiths EJ, Halestrap AP. 2011. The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemia. Biochem J 436: 493-505.

 80. Chouchani ET, Pell VR, Gaude E, Aksentijevi D, Sundier S, Robb ELet al. 2014. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature.

 81. Murry CE, Richard VJ, Reimer KA, Jennings RB. 1990. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 66: 913-931.

 82. Kida M, Fujiwara H, Ishida M, Kawai C, Ohura M, Miura Iet al. 1991. Ischemic preconditioning preserves creatine phosphate and intracellular pH. Circulation 84: 2495-2503.

 83. Kobara M, Tatsumi T, Matoba S, Yamahara Y, Nakagawa C, Ohta Bet al. 1996. Effect of ischemic preconditioning on mitochondrial oxidative phosphorylation and high energy phosphates in rat hearts. J Mol Cell Cardiol 28: 417-428.

 84. Yabe K, Nasa Y, Sato M, Iijima R, Takeo S. 1997. Preconditioning preserves mitochondrial function and glycolytic flux during an early period of reperfusion in perfused rat hearts. Cardiovasc Res 33: 677-685.

 85. Fryer RM, Eells JT, Hsu AK, Henry MM, Gross GJ. 2000. Ischemic preconditioning in rats: role of mitochondrial K(ATP) channel in preservation of mitochondrial function. Am J Physiol Heart Circ Physiol 278: H305-H312.

 86. Laclau MN, Boudina S, Thambo JB, Tariosse L, Gouverneur G, Bonoron-Adele Set al. 2001. Cardioprotection by ischemic preconditioning preserves mitochondrial function and functional coupling between adenine nucleotide translocase and creatine kinase. J Mol Cell Cardiol 33: 947-956.

 87. Murphy E, Steenbergen C. 2013. Did a classic preconditioning study provide a clue to the identity of the mitochondrial permeability transition pore? Circ Res 113: 852-855.

 88. Cohen MV, Yang XM, Downey JM. 2007. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 115: 1895-1903.

 89. Asimakis GK, Inners-McBride K, Medellin G, Conti VR. 1992. Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart. Am J Physiol 263: H887-H894.

 90. Steenbergen C, Perlman ME, London RE, Murphy E. 1993. Mechanism of preconditioning. Ionic alterations. Circ Res 72: 112-125.

 91. Wolfe CL, Sievers RE, Visseren FL, Donnelly TJ. 1993. Loss of myocardial protection after preconditioning correlates with the time course of glycogen recovery within the preconditioned segment. Circulation 87: 881-892.

 92. Xiao XH, Allen DG. 1999. Role of Na(+)/H(+) exchanger during ischemia and preconditioning in the isolated rat heart. Circ Res 85: 723-730.

 93. Xiao XH, Allen DG. 2000. Activity of the Na(+)/H(+) exchanger is critical to reperfusion damage and preconditioning in the isolated rat heart. Cardiovasc Res 48: 244-253.

 94. Avkiran M, Gross G, Karmazyn M, Klein H, Murphy E, Ytrehus K. 2001. Na+/H+ exchange in ischemia, reperfusion and preconditioning. Cardiovasc Res 50: 162-166.

 95. Snabaitis AK, Cuello F, Avkiran M. 2008. Protein kinase B/Akt phosphorylates and inhibits the cardiac Na+/H+ exchanger NHE1. Circ Res 103: 881-890.

 96. Hori M, Kitakaze M, Sato H, Takashima S, Iwakura K, Inoue Met al. 1991. Staged reperfusion attenuates myocardial stunning in dogs. Role of transient acidosis during early reperfusion. Circulation 84: 2135-2145.

 97. Fujita M, Asanuma H, Hirata A, Wakeno M, Takahama H, Sasaki Het al. 2007. Prolonged transient acidosis during early reperfusion contributes to the cardioprotective effects of postconditioning. Am J Physiol Heart Circ Physiol 292: H2004-H2008.

 98. Hausenloy DJ, Yellon DM. 2004. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448-460.

 99. Hausenloy DJ, Yellon DM. 2007. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12: 217-234.

 100. Lecour S. 2009. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 47: 32-40.

 101. Hausenloy DJ, Lecour S, Yellon DM. 2010. RISK and SAFE pro-survival signalling pathways in ischaemic postconditioning: Two sides of the same coin. Antioxid Redox Signal.

 102. Hausenloy DJ, Tsang A, Yellon DM. 2005. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15: 69-75.

 103. Breivik L, Helgeland E, Aarnes EK, Mrdalj J, Jonassen AK. 2011. Remote postconditioning by humoral factors in effluent from ischemic preconditioned rat hearts is mediated via PI3K/Akt-dependent cell-survival signaling at reperfusion. Basic Res Cardiol 106: 135-145.

 104. Bopassa JC, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ovize M. 2006. PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res 69: 178-185.

 105. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. 2006. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38: 414-419.

 106. Bijur GN, Jope RS. 2003. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J Neurochem 87: 1427-1435.

 107. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EMet al. 2002. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Circ Res 90: 390-397.

 108. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MVet al. 2005. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97: 329-336.

 109. Garlid KD, Costa AD, Cohen MV, Downey JM, Critz SD. 2004. Cyclic GMP and PKG activate mito K(ATP) channels in isolated mitochondria. Cardiovasc J S Afr 15: S5.

 110. Cohen P, Frame S. 2001. The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776.

 111. Tong H, Imahashi K, Steenbergen C, Murphy E. 2002. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase--dependent pathway is cardioprotective. Circ Res 90: 377-379.

 112. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. 2008. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117: 2761-2768.

 113. Nishino Y, Webb IG, Davidson SM, Ahmed AI, Clark JE, Jacquet Set al. 2008. Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res 103: 307-314.

 114. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KWet al. 2004. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549.

 115. Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh Ket al. 2007. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol 43: 564-570.

 116. Das S, Wong R, Rajapakse N, Murphy E, Steenbergen C. 2008. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res 103: 983-991.

 117. Tanno M, Kuno A, Ishikawa S, Miki T, Kouzu H, Yano Tet al. 2014. Translocation of Glycogen Synthase Kinase-3beta (GSK-3beta), a Trigger of Permeability Transition, Is Kinase Activity-dependent and Mediated by Interaction with Voltage-dependent Anion Channel 2 (VDAC2). J Biol Chem 289: 29285-29296.

 118. Zuurbier CJ, Smeele KM, Eerbeek O. 2009. Mitochondrial hexokinase and cardioprotection of the intact heart. J Bioenerg Biomembr 41: 181-185.

 119. Nederlof R, Eerbeek O, Hollmann MW, Southworth R, Zuurbier CJ. 2014. Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart. Br J Pharmacol 171: 2067-2079.

 120. Deuchar GA, Opie LH, Lecour S. 2007. TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning. Life Sci 80: 1686-1691.

 121. Suleman N, Somers S, Smith R, Opie LH, Lecour SC. 2008. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 79: 127-133.

 122. Lacerda L, Somers S, Opie LH, Lecour S. 2009. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 84: 201-208.

 123. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. 2006. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 149: 5-13.

 124. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. 2010. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 105: 771-785.

 125. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck Tet al. 2009. Function of mitochondrial Stat3 in cellular respiration. Science 323: 793-797.

 126. Ong SB, Hausenloy DJ. 2010. Mitochondrial morphology and cardiovascular disease. Cardiovasc Res 88: 16-29.

 127. Ong SB, Hall AR, Hausenloy DJ. 2013. Mitochondrial dynamics in cardiovascular health and disease. Antioxid Redox Signal 19: 400-414.

 128. Hall AR, Hausenloy DJ. 2012. The shape of things to come: mitochondrial fusion and fission in the adult heart. Cardiovasc Res 94: 391-392.

 129. Hall AR, Burke N, Dongworth RK, Hausenloy DJ. 2014. Mitochondrial fusion and fission proteins: novel therapeutic targets for combating cardiovascular disease. Br J Pharmacol 171: 1890-1906.

 130. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. 2010. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 121: 2012-2022.

 131. Cribbs JT, Strack S. 2007. Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep 8: 939-944.

 132. Chang CR, Blackstone C. 2007. Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J Biol Chem 282: 21583-21587.

 133. Parra V, Verdejo HE, Iglewski M, Del CA, Troncoso R, Jones Det al. 2014. Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the Akt-mTOR-NFkappaB-Opa-1 signaling pathway. Diabetes 63: 75-88.

 134. Kamga PC, Mo L, Quesnelle K, Dagda RK, Murillo D, Geary Let al. 2014. Nitrite activates protein kinase A in normoxia to mediate mitochondrial fusion and tolerance to ischaemia/reperfusion. Cardiovasc Res 101: 57-68.

 135. Sanchez G, Fernandez C, Montecinos L, Domenech RJ, Donoso P. 2011. Preconditioning tachycardia decreases the activity of the mitochondrial permeability transition pore in the dog heart. Biochem Biophys Res Commun 410: 916-921.

 136. Hausenloy D, Wynne A, Duchen M, Yellon D. 2004. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation 109: 1714-1717.

 137. Ichas F, Jouaville LS, Mazat JP. 1997. Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals. Cell 89: 1145-1153.

 138. Ichas F, Mazat JP. 1998. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta 1366: 33-50.

 139. De Giorgi F, Lartigue L, Ichas F. 2000. Electrical coupling and plasticity of the mitochondrial network. Cell Calcium 28: 365-370.

 140. Petronilli V, Miotto G, Canton M, Brini M, Colonna R, Bernardi Pet al. 1999. Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 76: 725-734.

 141. Katoh H, Nishigaki N, Hayashi H. 2002. Diazoxide opens the mitochondrial permeability transition pore and alters Ca2+ transients in rat ventricular myocytes. Circulation 105: 2666-2671.

 142. Saotome M, Katoh H, Yaguchi Y, Tanaka T, Urushida T, Satoh Het al. 2009. Transient opening of mitochondrial permeability transition pore by reactive oxygen species protects myocardium from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 296: H1125-H1132.

 143. Korge P, Yang L, Yang JH, Wang Y, Qu Z, Weiss JN. 2011. Protective role of transient pore openings in calcium handling by cardiac mitochondria. J Biol Chem 286: 34851-34857.

 144. Altschuld RA, Hohl CM, Castillo LC, Garleb AA, Starling RC, Brierley GP. 1992. Cyclosporin inhibits mitochondrial calcium efflux in isolated adult rat ventricular cardiomyocytes. Am J Physiol 262: H1699-H1704.

 145. Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SAet al. 2010. Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest 120: 3680-3687.

 146. Menazza S, Wong R, Nguyen T, Wang G, Gucek M, Murphy E. 2013. CypD(-/-) hearts have altered levels of proteins involved in Krebs cycle, branch chain amino acid degradation and pyruvate metabolism. J Mol Cell Cardiol 56: 81-90.

 147. Nguyen TT, Wong R, Menazza S, Sun J, Chen Y, Wang Get al. 2013. Cyclophilin D modulates mitochondrial acetylome. Circ Res 113: 1308-1319.

 148. Luvisetto S, Basso E, Petronilli V, Bernardi P, Forte M. 2008. Enhancement of anxiety, facilitation of avoidance behavior, and occurrence of adult-onset obesity in mice lacking mitochondrial cyclophilin D. Neuroscience 155: 585-596.

 149. Tubbs E, Theurey P, Vial G, Bendridi N, Bravard A, Chauvin MAet al. 2014. Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Integrity Is Required for Insulin Signaling and Is Implicated in Hepatic Insulin Resistance. Diabetes 63: 3279-3294.

 150. Ferdinandy P, Schulz R, Baxter GF. 2007. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458.

 151. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. 2014. Interaction of cardiovascular risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning: an update**.** Pharmacol Rev.

 152. Huhn R, Heinen A, Hollmann MW, Schlack W, Preckel B, Weber NC. 2010. Cyclosporine A administered during reperfusion fails to restore cardioprotection in prediabetic Zucker obese rats in vivo. Nutr Metab Cardiovasc Dis 20: 706-712.

 153. Peart JN, Pepe S, Reichelt ME, Beckett N, See HL, Ozberk Vet al. 2014. Dysfunctional survival-signaling and stress-intolerance in aged murine and human myocardium. Exp Gerontol 50: 72-81.

 154. Schneider A, Ad N, Izhar U, Khaliulin I, Borman JB, Schwalb H. 2003. Protection of myocardium by cyclosporin A and insulin: in vitro simulated ischemia study in human myocardium. Ann Thorac Surg 76: 1240-1245.

 155. Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM. 2005. Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol 289: H237-H242.

 156. Rees PS, Davidson SM, Harding SE, McGregor C, Elliot PM, Yellon DMet al. 2013. The mitochondrial permeability transition pore as a target for cardioprotection in hypertrophic cardiomyopathy. Cardiovasc Drugs Ther 27: 235-237.

 157. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton Net al. 2008. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473-481.

 158. Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez Iet al. 2010. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 55: 1200-1205.

 159. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJet al. 2010. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87: 406-423.

 160. Ghaffari S, Kazemi B, Toluey M, Sepehrvand N. 2013. The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. Cardiovasc Ther 31: e34-e39.

 161. Hausenloy D, Kunst G, Boston-Griffiths E, Kolvekar S, Chaubey S, John Let al. 2014. The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. Heart 100: 544-549.

 162. Chiari P, Angoulvant D, Mewton N, Desebbe O, Obadia JF, Robin Jet al. 2014. Cyclosporine protects the heart during aortic valve surgery. Anesthesiology 121: 232-238.

 163. Cour M, Loufouat J, Paillard M, Augeul L, Goudable J, Ovize Met al. 2011. Inhibition of mitochondrial permeability transition to prevent the post-cardiac arrest syndrome: a pre-clinical study. Eur Heart J 32: 226-235.

 164. Gill RS, Manouchehri N, Liu JQ, Lee TF, Cho WJ, Thiesen Aet al. 2012. Cyclosporine treatment improves cardiac function and systemic hemodynamics during resuscitation in a newborn piglet model of asphyxia: a dose-response study. Crit Care Med 40: 1237-1244.

 165. Argaud L, Gateau-Roesch O, Chalabreysse L, Gomez L, Loufouat J, Thivolet-Bejui Fet al. 2004. Preconditioning delays Ca2+-induced mitochondrial permeability transition. Cardiovasc Res 61: 115-122.

 166. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert Det al. 2005. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 38: 367-374.

 167. Malouitre S, Dube H, Selwood D, Crompton M. 2010. Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochem J 425: 137-148.

 168. Schaller S, Paradis S, Ngoh GA, Assaly R, Buisson B, Drouot Cet al. 2010. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J Pharmacol Exp Ther 333: 696-706.

 169. Atar D, Arheden H, Berdeaux A, Bonnet JL, Carlsson M, Clemmensen Pet al. 2014. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur Heart J. 2014 Sep 1. pii: ehu331. [Epub ahead of print]

**Table 1. Major studies investigating MPTP inhibition in the human heart: *ex vivo* and clinical studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ***Study*** | ***Acute myocardial ischemia-reperfusion setting*** | ***CsA treatment protocol*** | ***End-point*** | ***Protection achieved?*** |
| Schneider *et al* [154] | Human right atrial appendage tissue subjected to simulated IRI (harvested from CABG patients) | Pre-treatment with CsA (0.2 µmol/L)  | CsA pre-treatment improved cell viability | Yes |
| Shanmuganathan *et al* [155] | Human right atrial trabeculae and cardiomyocytes subjected to simulated IRI | Treatment with CsA (0.2 µmol/L) at the onset of simulated reperfusion | CsA at reperfusion improved recovery of baseline contractile function, reduced cell death, and inhibited MPTP opening. | Yes |
| Rees *et al* [156] | Ventricular cardiomyocytes from HCM patients undergoing surgical myectomy Oxidative stress-induced MPTP opening | Pre-treatment with CsA (0.2 µmol/L)  | CsA Inhibited MPTP opening in diseased cardiac tissue. | Yes |
| Piot *et al* [157] | 58 STEMI patients undergoing PPCI. | Single IV bolus of either CsA (2.5 mg/kg) or placebo given 10 min prior to PPCI | 44% reduction in MI size (72 hours AUC total CK)20% reduction in MI size (Cardiac MRI subset)28% reduction in MI size and smaller LVESV on cardiac MRI at 6 mths[158] | Yes |
| Ghaffari *et al* [160] | 101 STEMI patients undergoing thrombolysis. | Single IV bolus of either CsA (2.5 mg/kg) or placebo given 10 min prior to thrombolysis | No difference in MI size, occurrence of major arrhythmias, heart failure, left ventricular ejection fraction (LVEF) | No |
| Hausenloy *et al* [161] | 78 patients undergoing coronary artery bypass graft (CABG) surgery | Single IV bolus of either CsA (2.5 mg/kg) or placebo given prior surgical incision | Reduction in peak Trop T in patients with longer cardiopulmonary bypass times. | Yes  |
| Chiari *et al* [162] | 61 adult patients undergoing aortic valve surgery | Single IV bolus of either CsA (2.5 mg/kg) or placebo given prior to reperfusion at the time of declamping the aorta | Reduction 72-hour area under the curve for Trop I. | Yes |
| CYCLosporinEA in Reperfused Acute Myocardial Infarction (CYCLE) ClinicalTrials.gov NCT01650662 | 444 STEMI patients undergoing PPCI Multi-center RCT  | Single IV bolus of either CsA (2.5 mg/kg) or placebo given 10 min prior to PPCI | Primary endpoint is ST-segment resolution ≥70% | Ongoing study |
| Cyclosporine and Prognosis in Acute Myocardial Infarction Patients (CIRCUS)ClinicalTrials.gov NCT01502774 | 972 STEMI patients undergoing PPCI Multi-center RCT | Single IV bolus of either CsA (2.5 mg/kg) or placebo given 10 min prior to PPCI  | Primary combined endpoint (total mortality, HHF, and increase of LVEDV>15%]) | Recruitment completed.Ongoing study |
| Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock (CLOTILDE)ClinicalTrials.gov NCT01901471 | 100 STEMI patients undergoing PPCI who have presented in cardiogenic shock  | Single IV bolus of either CsA (2.5 mg/kg) or placebo given 10 min prior to PPCI | Multi-organ failure, cardiac output, MI size, LV remodeling.  | Ongoing study |

CsA- cyclosporin-A, IRI- ischemia/reperfusion injury, HHF- hospitalization for heart failure, IV- intravenous, LVEDV- left ventricular end diastolic volume, LVEDV- left ventricular end systolic volume, MI- myocardial infarction, PPCI- primary percutaneous coronary intervention (PPCI), RCT-randomized clinical trial, STEMI- ST-segment elevation myocardial infarction, Trop T/I- Troponin T and I.